

Managing Subarachnoid Hemorrhage in the Neurocritical Care Unit

Justin M. Caplan, MD^a, Geoffrey P. Colby, MD, PhD^b,
Alexander L. Coon, MD^c, Judy Huang, MD^d,
Rafael J. Tamargo, MD^{e,*}

KEYWORDS

- Aneurysm • Subarachnoid hemorrhage • Vasospasm • Delayed cerebral ischemia
- Neurocritical care

KEY POINTS

- The management of patients with aneurysmal subarachnoid hemorrhage is challenging and requires a multidisciplinary team approach, and is best done at high-volume centers.
- There is a paucity of randomized, blinded, placebo-controlled, prospective trials to aid in the management of aneurysmal subarachnoid hemorrhage.
- The critical care management of aneurysmal subarachnoid hemorrhage varies between patients with microsurgical clipping and those with endovascular occlusion, and the critical care practitioner should be aware of these differences.
- Much of the morbidity from aneurysmal subarachnoid hemorrhage occurs in a delayed manner following the initial hemorrhage. It is the role of the neurocritical care unit to understand and manage these complications.

INTRODUCTION

Aneurysmal subarachnoid hemorrhage (aSAH) can be a devastating condition that leads to significant morbidity and mortality. Over the past several decades, there has been an overall decrease in the incidence of strokes in high-income countries, but without a concomitant decrease in the incidence of SAH.¹ Unlike other causes of SAH (ie, trauma), aSAH represents a unique physiology, which sets up a cascade of events that leads to further pathologic processes involving multiple organ systems.

If a patient survives the initial hemorrhage, it is these pathologic processes that are the source of the significant morbidity and mortality following aSAH. As such, a thorough understanding of these processes and their management are a necessity for any practitioner caring for patients with aSAH. Furthermore, given the complexity of the management of these patients, this care is best done in a dedicated neurocritical care unit (NCCU).

In 2011 and 2012, 2 sets of guidelines were published on the management of aSAH.^{2,3} These guidelines by the Neurocritical Care Society and

Disclosures: None.

^a Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Room 6007, Baltimore, MD 21287, USA; ^b Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Room 6115C, Baltimore, MD 21287, USA; ^c Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Room 6115E, Baltimore, MD 21287, USA; ^d Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Room 6115F, Baltimore, MD 21287, USA; ^e Division of Cerebrovascular Neurosurgery, Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Room 6115G, Baltimore, MD 21287, USA

* Corresponding author.

E-mail address: rtamarg@jhmi.edu

Neurosurg Clin N Am 24 (2013) 321–337

<http://dx.doi.org/10.1016/j.nec.2013.02.008>

1042-3680/13/\$ – see front matter © 2013 Elsevier Inc. All rights reserved.

the American Heart Association/American Stroke Association (AHA/ASA), and their supporting articles, provide comprehensive reviews of the literature combined with expert consensus opinions. These articles note that there is a paucity of prospective, randomized, placebo-controlled trials in the literature showing that an intervention improves outcome, which might aid in guiding the management of aSAH. In fact, the use of nimodipine (Nimotop) is the only such intervention supported by level 1A class evidence.³ As such, much of the management of this disease is left to the interpretation of the literature by an experienced clinician. The goal of this article is to review the pertinent literature in a condensed format, in combination with our own experiences in managing these patients, in an attempt to provide a practical aid to those managing this challenging disease in the NCCU.

In addition to reviewing the evidence behind the current management of aSAH in the NCCU, this article is also meant to serve as a practical reference to those who are involved in the day-to-day management of these patients (ie, residents and fellows). To this end a table is included to aid with admission orders, and which can be used as a quick reference on daily NCCU rounds. In their NCCU, we often use a “systems-based” method of rounding, and have organized the table and article in this manner (**Table 1**).

CARE SETTING

The care of patients with aSAH requires a multidisciplinary approach. Team members include neurosurgeons, neurointensivists, neurologists, neuroradiologists, and interventional neuroradiologists. Patients also require specialized critical care nursing with specialized training in neurosciences. We believe that these patients are best served in dedicated NCCUs that treat a high volume of such patients. This scenario is also supported in the literature, which shows that outcomes are improved at high-volume centers.⁴ It is also important that patients be transferred expeditiously to the high-volume centers, as rebleeding before transfer or during transfer is reported.⁵

NEUROLOGIC *Hydrocephalus*

Hydrocephalus is a known complication of aSAH, first described experimentally in 1928 by Bagley.⁶ The incidence of acute hydrocephalus varies widely, and many studies report a range from 15% to 53%.^{7–13} The incidence of patients with

SAH who go on to require permanent shunting also varies widely in the literature. Shunt rates from 2.3% to 36% have been reported.^{7–16} This large variation is likely multifactorial, including varying indications for shunting across institutions and surgeons, effects of clot/blood removal from the subarachnoid space at the time of surgery, and fenestration of the lamina terminalis.

Hydrocephalus following aSAH can be of both the obstructive and the communicating variant. In obstructive hydrocephalus, there may be intraventricular extension of the subarachnoid blood or an intraparenchymal hematoma. In the communicating variant the ventricular system may be free of blood, but the arachnoid granulations may become obstructed by the subarachnoid blood, limiting reabsorption of cerebrospinal fluid (CSF). Recognition of the cause of the patient's hydrocephalus is important, as it can affect the means by which the hydrocephalus is treated (lumbar drain, external ventriculostomy drainage, endoscopic third ventriculostomy, shunt, and so forth).

There are many factors involved in managing hydrocephalus following subarachnoid hemorrhage that are important to the neurointensivist, including ventriculostomy or lumbar drain weaning, risk of aneurysmal rebleeding in the setting of CSF drainage, and indications and timing of permanent CSF diversion (ie, shunting).

The timing of ventriculostomy weaning and removal is not agreed upon. The role of rapid versus gradual weaning from external ventricular drainage (EVD) was examined in a prospective randomized trial by Klopfenstein and colleagues.¹⁷ In this study 81 patients with aSAH with EVDs were randomized to either rapid (24 hours) or gradual (96 hours) wean. This study found no difference in rates of shunt implantation between groups. The gradual-wean group did have longer stays in the intensive care unit (ICU) and hospital. However, we have found that persistence in ventriculostomy weaning is very effective in preventing the need for shunting. Serial EVD clamp trials are effective as long as the amount of CSF draining through the ventriculostomy decreases daily. Although this may lead to a more prolonged EVD wean and ICU/hospital stay, it reduces the number of shunts placed.

After initial ventriculostomy or lumbar drain placement, the risk of aneurysm rebleeding is often quoted as a concern against aggressive CSF drainage in the setting of an unsecured aneurysm. Some data suggest, however, that this is safe. Hellingman and colleagues¹⁸ retrospectively reviewed 34 patients who underwent EVD placement against matched controls with untreated hydrocephalus and a control without ventricular enlargement.

Rebleeding occurred in 21% of patients with treated hydrocephalus as well as untreated hydrocephalus, and 18% of those without hydrocephalus. In the lumbar puncture (LP) group, rebleeding occurred in 5% of patients, in 14% of patients with hydrocephalus without LP, and in none of the controls without hydrocephalus. It was concluded that there was no statistically significant difference between rebleeding in those patients treated with either EVD or LP versus those who were not. McIver and colleagues¹⁹ retrospectively reviewed 304 patients with aneurysmal subarachnoid hemorrhage. Of these patients, 45 had ventriculostomies placed. Rebleeding occurred in 5.4% of patients not undergoing ventriculostomy placement and in 4.4% of those who did undergo ventriculostomy placement. The ability to safely drain CSF following aSAH is important, as there are data to suggest it may lead to a reduction in vasospasm.²⁰

Temporary CSF diversion may typically be achieved with ventriculostomy, serial LPs, or lumbar catheter placement. Knowledge of the cause of the hydrocephalus is important, as this may influence a particular approach. We routinely use ventriculostomy as a means to achieve CSF diversion. This approach is well tolerated and, in addition to CSF drainage, allows for accurate measurement of intracranial pressure, which may be important, particularly in high-grade patients with a poor neurologic examination.

Shunt dependence following aSAH varies. Factors predicting the development of shunt-dependent hydrocephalus include age, acute hydrocephalus, ventilation on admission, posterior circulation, and giant aneurysms.¹⁴ Fenestration of the lamina terminalis is a microsurgical maneuver, the utility of which is debated. In our experience, routine fenestration of the lamina terminalis is associated with an 80% decrease in the incidence of shunt-dependent hydrocephalus.⁸ We routinely perform this straightforward microsurgical technique in all cases of aSAH where access to the lamina terminalis is easily obtainable (ie, fronto-spheno-temporal [pterional] craniotomies). However, the issue of fenestrating the lamina terminalis is debated, as some literature suggests it does not reduce the incidence of shunt-dependent hydrocephalus.¹⁵ The AHA guidelines do not recommend this maneuver, and classify the evidence as level IIIB.³

Seizures

Seizures after aSAH hemorrhage are common. One retrospective review found a prevalence of 15.2% in 547 patients.²¹ Seizure frequency in subarachnoid hemorrhage after surgery was 9.4% in the 307

patients studied prospectively by Ohman.²² Furthermore, in this study a history of hypertension was found to be a significant risk factor for the development of epilepsy after aSAH and surgery. Epilepsy developed in 7% of 247 patients alive with follow-up 12 months after aSAH.²³ Subdural hematoma and cerebral infarction were predictors of epilepsy.

The risk of seizures in patients undergoing clip occlusion or coil embolization of ruptured aneurysms was assessed in the International Subarachnoid Aneurysm Trial (ISAT).²⁴ There was an overall incidence of seizures in 10.9% of the patients. Among those patients randomized to endovascular intervention, 8.3% had seizures, whereas 13.6% of patients randomized to open surgery had seizures, a difference that was found to be significant. Furthermore, on long-term follow-up after discharge, the risk of seizures was also significantly greater in the neurosurgical group. The study also identified the following risk factors for developing seizures: younger age, Fisher grade greater than 1 on computed tomography (CT), delayed ischemic neurologic deficit due to vasospasm, thromboembolic complication, and middle cerebral artery (MCA) location of the aneurysm.

Lanzino and colleagues²⁵ reviewed 56 articles from 1980 to 2010 on the topic of the incidence and treatment of seizures after aneurysmal subarachnoid hemorrhage. Seizures occurred at the time of SAH in 4% to 26% of patients. Only a small proportion of patients had a seizure after admission but before aneurysm treatment. This review also addressed the role of anticonvulsants after SAH. The study notes that there are no randomized controlled trials addressing the safety and efficacy of antiepileptics in SAH. The AHA/ASA guidelines are similarly vague, stating that “the use of prophylactic anticonvulsants may be considered in the immediate post-hemorrhagic period.”³ There are data to suggest that the use of phenytoin (Dilantin, Phenytek) for seizure prophylaxis is associated with poor functional outcome.²⁶

The duration of prophylactic anticonvulsant use is also not well agreed upon. A short course of phenytoin (3 days), however, may be equivalent to a longer (7-day) course, but with fewer side effects in preventing seizures.²⁷ While the routine use of antiepileptic drugs (AEDs) in SAH is common, it is not trivial. A study pooling the data of 3552 patients from 4 prospective, randomized, double-blind, placebo-controlled trials from 1991 to 1997 looked at the outcomes in patients with subarachnoid hemorrhage treated with AEDs.²⁸ In this study, 65.1% of patients received antiepileptic drugs. Patients who received treatment with AEDs had a worse outcome based on the Glasgow Outcome

Table 1
Admission orders and rounding template for patients with aSAH in the NCCU

System	Orders	Notes
General	Admit to NCCU, neurosurgery, attending of record	
Neurologic	Noncontrast head CT Conventional 4-vessel cerebral-angiogram Aneurysm precautions Levetiracetam 1 g q12 h q6 h Na/K checks Na goal: 135–145 Ventriculostomy-if symptomatic hydrocephalus Dexamethasone (Decadron) 4 mg q6 h × 24 h Daily TCDs Nimodipine 60 mg q4 h × 21 d	Dark, quiet room, limited interruptions Seizure prophylaxis To monitor for CSW/SIADH May be adjusted depending on patient's clinical status and evidence of cerebral edema Pop-off set to 15–20 mm Hg in setting of unsecured aneurysm. After aneurysm occlusion, pop-off may be lowered depending on clinical scenario
Cardiac	SBP goal <160 MAP goal >70 Baseline ECG Baseline echocardiogram	Nicardipine (Cardene) continuous infusion if needed. SBP goal may be liberalized if vasospasm/DCI
Pulmonary	Incentive spirometry Chest radiograph Ventilator settings if patient requires mechanical ventilation	On admission and then daily if intubated

Renal	IV fluids: 0.9% normal saline at 150 mL/h Goal euvolemia	May use 2% or 3% hypertonic saline based on sodium goal Volume status goal may change as clinical scenario changes (ie, goal hypervolemia in setting of vasospasm/DCI)
GI	NPO on admission Pantoprazole (Protonix) 40 mg q24 h	Resume enteral feeds when clinically stable GI ulcer prophylaxis
ID	Follow temperature curves Periprocedural antibiotics Fever workup if $T_{\max} > 38.4^{\circ}\text{C}$	Initiate cooling measures if persistently febrile despite antipyretics Cefazolin 1–2 g $\times$ 1 for EVD or lumbar drain placement Cefazolin 1–2 g q8 $\times$ 3 doses for craniotomy (may use clindamycin 600 mg if cefazolin allergy) Urine analysis, blood and urine cultures, CXR, $\pm$ CSF studies/culture
Endocrine	Glucose checks q4 h while NPO Insulin sliding scale	Glucose goal ≤ 150 mg/dL
Hematology	Hemoglobin goal ≥ 10 g/dL	
DVT prophylaxis	Compression stockings Sequential compression devices Unfractionated heparin 5000 units SC q8–12 h	Start 24 h after stable head CT or after craniotomy
Check labs	BMP, CBC, coags, type and screen, UA/urine culture, urine pregnancy test (if applicable)	
Consent	Consent for angiogram, intraoperative angiogram, ventriculostomy, craniotomy	Done at time of admission to NCCU

Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; BMP, basic metabolic panel; CBC, complete blood count; coags, coagulation panel; CSF, cerebrospinal fluid; CSW, cerebral salt wasting; CT, computed tomography; CXR, chest radiography; DCI, delayed cerebral ischemia; DVT, deep venous thrombosis; ECG, electrocardiography; EVD, external ventricular drainage; GI, gastrointestinal; ID, infectious disease; IV, intravenous; MAP, mean arterial pressure; NCCU, neurocritical care unit; NPO, nothing by mouth; q, every; SBP, systolic blood pressure; SC, subcutaneous; SIADH, syndrome of inappropriate antidiuretic hormone secretion; TCD, transcranial Doppler ultrasonography; UA, urinalysis.

Scale, and were more likely to have vasospasm, neurologic deterioration, cerebral infarction, and elevated temperatures during hospitalization. We routinely use levetiracetam (Keppra), 500 to 1000 mg every 12 hours, for seizure prophylaxis. This medication has a favorable side-effect profile in comparison with phenytoin. The duration of therapy is tailored to the individual patient, and takes into account the extent and location of SAH/intraparenchymal hemorrhage and the presence or absence of seizures.

Rebleeding

Rebleeding rates after aSAH vary in the literature. Starke and Connolly,²⁹ on behalf of the participants of the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage, recently published a review of the literature on this topic. Early studies (through 1990) showed that rebleeding rates for untreated aneurysms were 4% within the first 24 hours, 1% to 2% per day for the next 14 days, 50% for the first 6 months, and 3% per year following this. In the ISAT trial, approximately 2.1% of patients rebled before treatment.³⁰ In the International Cooperative Study on the Timing of Aneurysm Surgery, rebleeding occurred in 6% of patients with planned surgery for days 0 to 3 and 22% in patients with planned surgery for days 15 to 32.³¹ In this study, after the initial effects of the hemorrhage and vasospasm, rebleeding was the next largest cause of poor results.³² This finding has led to the standard of care that aneurysms should be occluded as soon as possible following rupture.

Many risk factors can help to predict rebleeding. Naidech and colleagues³³ looked at 574 patients enrolled in the Columbia University SAH Outcomes project. Rebleeding occurred in 6.9% of patients, 73% of which occurred in the first 3 days. In their multilogistic regression model, independent predictors of rebleeding were Hunt-Hess grade on admission and maximal aneurysm diameter. Of note, rebleeding was associated with a decrease in survival with functional independence. Timing of rebleeding was also related to Hunt-Hess grade. Patients with higher grades (IV and V) rebled earlier than those with lower grades. Rebleeding time did not correlate with aneurysm size. Patients with rebleeding have worse outcomes compared with those who do not, including higher rates of brain death and poor outcomes.³⁴

Risk of rebleeding following treatment of ruptured intracranial aneurysms was studied in the Cerebral Aneurysm Rerupture After Treatment (CARAT) study,³⁵ which looked at 1001 patients

across 9 centers treated with either coil embolization or surgical clipping. In this study there were 19 reruptures following treatment, 58% of which led to death. Degree of aneurysm occlusion was associated with the risk of rerupture. There was no statistically significant difference between rebleeding risk following coil embolization in comparison with surgical clipping.

Given the important finding that rebleeding is associated with worse outcomes, many have sought to identify interventions that can reduce this risk. As mentioned earlier, early aneurysm occlusion is one such intervention that has been an important development in the management of these patients. Another intervention that has been studied is the use of antifibrinolytic therapy, which has been evaluated mainly with the antifibrinolytics tranexamic acid (Lysteda, Cyklokapron) and ϵ -aminocaproic acid (EACA) (Amicar). The use of tranexamic acid (TXA) and EACA has been studied extensively. The goal of this therapy is to prevent clot dissipation by means of inhibiting fibrinolysis. However, despite the theoretical benefits, clinical outcomes have been varied.

In 2003 a Cochrane review looked at the use of antifibrinolytic therapy in aSAH, and concluded there was no benefit for poor outcome or death.³⁶ There was a reduction in rebleeding but this was countered by the increased risk of cerebral ischemia, therefore the review rejected the routine use of antifibrinolytic therapy in aSAH.

Given worse outcomes from delayed ischemia in patients treated with antifibrinolytics, more recent studies have evaluated the potential benefit of a short course of antifibrinolytic therapy. A prospective, randomized controlled trial published in 2002 looked at the use of early TXA (1 g) at the time of SAH diagnosis and 1 g every 6 hours until the aneurysm was occluded.³⁷ However, treatment with TXA did not exceed 72 hours. A total of 505 patients were randomized (254 to TXA, and 251 to control). Rebleeding decreased from 10.8% in controls to 2.4% in the treatment group. A prospective observational study looked at the use of EACA at the time of SAH diagnosis, but continued only for a maximum of 72 hours.³⁸ The study compared 73 patients treated with EACA and 175 patients not treated with EACA. This protocol resulted in a significant decrease in bleeding among those patients treated with EACA (2.7%) versus non-EACA treated patients (11.4%). Of importance, as had been previously seen in trials with prolonged use of antifibrinolytic therapy, there were no differences in ischemic complications between those treated and those not treated. There was, however, an increase in the incidence of deep venous thrombosis (DVT) in the treatment

group. There was no statistically significant difference in outcome between cohorts.

Given these data, the AHA/ASA SAH guidelines offer a Class IIA recommendation that it is reasonable to give antifibrinolytic therapy for less than 72 hours in patients with an unavoidable delay in aneurysm occlusion, a significant risk of rebleeding, and no medical contraindication.³ We currently do not routinely use antifibrinolytic therapy. However, we do aim to treat all ruptured aneurysms within 24 hours of admission, thereby reducing the risk of rerupture.

Vasospasm and Delayed Cerebral Ischemia

Nomenclature

aSAH is associated with significant morbidity and mortality. Much of the morbidity is secondary to cerebral ischemia, which can occur in a delayed manner (ie, several days after the ictus). If severe enough, the ischemia can lead to brain tissue infarction. Although this has often been correlated with angiographic vessel narrowing ("vasospasm"), vasospasm can occur without ischemia/infarction, and ischemia/infarction can occur without vasospasm.³⁹ Vasospasm has been a well-known sequela of SAH since early descriptions by Robertson⁴⁰ in 1949 and Ecker and Riemenschneider⁴¹ in 1951. Owing to the large variability in nomenclature, an international ad hoc panel of experts was assembled to propose a universal definition of delayed cerebral ischemia (DCI) to standardize outcome measures.⁴² The investigators correctly observe that the diagnosis of DCI is one of exclusion. We make the diagnosis of DCI when there is a deterioration in the neurologic examination, etiology such as hydrocephalus, cerebral salt wasting (CSW), infection, and hemorrhage have been ruled out, and the deterioration improves with triple-H therapy within 6 to 12 hours; or, if there is no improvement, an angiogram is obtained to show radiographic vessel narrowing. It is important to recognize failure to respond to therapy, as lack of early improvement leads to a high risk of poor outcomes and thus may be an indication for conventional angiography.⁴³

It is important to distinguish vasospasm (a radiographic finding) from clinical deterioration secondary to DCI, which can be a multifactorial process that includes vessel narrowing (ie, vasospasm).^{42,44} A prospective study of 508 patients with subarachnoid hemorrhage also supports the notion that DCI is a more meaningful definition than arterial narrowing alone.⁴⁵ Given the significant morbidity and mortality associated with vasospasm and DCI, over the past several decades a significant effort

has been made to establish monitoring and interventions that can improve outcomes from this process. A comprehensive review of all of these trials and measures is beyond the scope of this article; however, an outline follows of what we believe to be the most important, including transcranial Doppler ultrasonography (TCD), calcium-channel blockers, triple-H therapy, endovascular therapy, endothelin receptor antagonists, and statins.

Monitoring for vasospasm and DCI

Monitoring for the development of vasospasm and DCI remains an important role of the NCCU. In addition to serial neurologic examinations and imaging studies (ie, CT, CT perfusion, and conventional angiography), TCD is an important method for evaluating the cerebral vasculature. Despite the widespread use of TCD, however, its accuracy in predicting DCI and vasospasm is limited.^{46,47} In a review of 441 patients with aSAH, almost 40% of patients with DCI did not have TCD velocities above the vasospasm threshold of 120 cm/s.⁴⁶ We use TCD data as an adjuvant to the clinical examination and other diagnostic modalities (such as CT perfusion scanning), and will follow trends in TCD velocities, but elevation in these numbers alone without clinical evidence of DCI does not lead them to make interventions.

Calcium-channel blockers

There are few multi-institutional, randomized, placebo-controlled, double-blind trials in the neurosurgical literature on improvement of outcomes that are available to guide management. The use of nimodipine following aSAH, however, represents one such trial.⁴⁸ The use of nimodipine following aSAH was pioneered by Allen and colleagues⁴⁸ at Johns Hopkins University School of Medicine. In this trial, 125 neurologically intact patients with aSAH were randomized to either nimodipine or placebo for 21 days. Only 1 patient of 56 treated with nimodipine versus 8 of 60 in the placebo group developed a persistent deficit from cerebral arterial spasm ($P = .03$).

Recently, a meta-analysis was completed looking at the use of calcium antagonists for aSAH.^{49,50} The review included 16 trials with 3361 patients. Three of these trials included magnesium sulfate. Oral nimodipine provided a relative risk of 0.67 (95% confidence interval [CI] 0.55–0.81) for poor outcome. There was no statistically significant reduction for other calcium-channel antagonists alone or with intravenous nimodipine. Calcium-channel antagonists overall reduced the occurrence of secondary ischemia with a relative risk of 0.66 (95% CI 0.59–0.75). Based on this evidence, the investigators

recommend oral nimodipine, 60 mg every 4 hours for 21 days⁵⁰; this is also our practice.

As already mentioned, it has been hypothesized that magnesium sulfate may also reduce the risk of DCI and poor outcome after aSAH. The MASH-2 (Magnesium for Aneurysmal Subarachnoid Hemorrhage) trial was a phase 3 randomized, placebo-controlled, multicenter trial aimed at addressing this question.⁵¹ Patients were randomized to magnesium sulfate, 64 mmol/d, or placebo. There were 606 patients in the magnesium group and 597 in the placebo group. Poor outcome was found in 26.2% of patients receiving magnesium and in 25.3% of patients receiving placebo (relative risk 1.03, 95% CI 0.85–1.25). Based on this evidence and an updated review of meta-analysis data, the investigators do not recommend intravenous magnesium sulfate after aSAH. We do not use magnesium sulfate in managing these patients.

Triple-H therapy

The treatment of vasospasm following subarachnoid hemorrhage has classically been the so-called triple-H therapy, consisting of hypertension, hypervolemia, and hemodilution. This therapy evolved from 1972 to 1982, initially as monotherapies and subsequently as a combination of all 3.^{52–55} The relative importance of each component of triple-H therapy has recently come under review. The literature seems to support that of each component; hypertension is the most important in increasing cerebral blood flow (CBF) and/or oxygenation, whereas hypervolemia does not increase CBF.^{56–58} Further studies are needed to best identify the role triple-H therapy should play in managing vasospasm/DCI, as it is not a benign therapy and is associated with many complications, including pulmonary edema, hyponatremia, and myocardial infarction.⁵⁹ Furthermore, accurate hemodynamic management of these patients often requires invasive catheter lines. We routinely use the PiCCO (Pulsion Medical Systems SE, Feldkirchen, Germany) catheter system in preference to traditional Swan-Ganz catheters in managing these patients.

In patients with unsecured, unruptured aneurysms, hypertensive, hypervolemia therapy seems to be safe and does not lead to rupture.⁶⁰ When hypotension is a concern, if nimodipine administration results in unwanted lowering of blood pressure, we will routinely change the dosage from 60 mg every 4 hours to 30 mg every 2 hours. This change often will mitigate the antihypertensive effects of this calcium-channel blocker while maintaining the total daily dose.

During triple-H therapy, we aim for a mean arterial pressure goal that is 20% above the patient's

baseline. If this fails to produce a favorable response in the patient, it will then be increased by another 10% of the new baseline. Extrapolating from the ischemic stroke guidelines, this elevation will be continued up to a systolic blood pressure of 220 mm Hg or diastolic blood pressure of 120 mm Hg.⁶¹

Endovascular management of vasospasm

Balloon catheter for angioplasty for vasospasm in aSAH was introduced in 1984.⁶² In their review of the literature, Hoh and Ogilvy⁶³ found a 62% rate of clinical improvement following balloon angioplasty, although this was associated with a 5% major complication rate and 1.1% rate of vessel rupture. The decision to proceed with angioplasty rather than intra-arterial vasodilators is beyond the scope of this article. For a recent review of the literature, see Kimball and colleagues.⁶⁴ We proceed with angiography in patients with suspected DCI/vasospasm who do not improve clinically within 6 to 12 hours of initiation of triple-H therapy. If vasospasm is found radiographically, it is treated with either angioplasty or intra-arterial vasodilators.

Inflammation and endothelin receptor antagonists and statins

As discussed earlier, DCI is a major source of morbidity following subarachnoid hemorrhage. Vasospasm is thought to play at least some role in this process. Laboratory evidence supports the hypothesis that vasospasm is at least partially mediated by inflammatory processes.^{65–68} Given this theory, considerable efforts have been made to evaluate promising therapies aimed at the inflammatory nature of vasospasm/DCI.

Endothelin, a vasoconstrictor, is thought to be a potential mediator of vasospasm, produced by a variety of cell types, including leukocytes in the CSF.^{69,70} As such, there have been efforts to show that endothelin antagonists (such as clazosentan) can improve vasospasm, and therefore improve outcomes in aSAH. The CONSCIOUS trials (Clazosentan to Overcome Neurologic Ischemia and Infarction Occurring after Subarachnoid Hemorrhage) have sought to answer this question. CONSCIOUS-1 was a randomized, double-blind, placebo-controlled phase 2b dose-finding trial, which found that clazosentan significantly decreased moderate and severe angiographic vasospasm in a dose-dependent manner.⁷¹ Encouragingly the investigators also found that there was some evidence suggesting a decrease in morbidity and mortality related to vasospasm. However, the study, was not powered to detect differences in clinical outcome.

The CONSCIOUS-2 trial was a randomized, double-blind, placebo-controlled phase 3 trial to assess the efficacy in reducing all-cause mortality, vasospasm-related new infarcts, delayed ischemic neurologic deficit secondary to vasospasm, and rescue therapy for vasospasm in patients with aSAH undergoing surgical clipping.⁷² The study failed to show any significant benefit in clazosentan use. The CONSCIOUS-3 trial aimed to assess the same question in aSAH patients undergoing endovascular coiling.⁷³ This study was ended prematurely given the results of the CONSCIOUS-2 trial. The study did show a significant reduction of vasospasm-related morbidity and all-cause mortality at the high dose, but there was no statistically significant improvement in patient outcome. A recent review of the literature further supports these findings, and do not support the use of endothelin receptor antagonists for patients with aSAH.⁷⁴

Given the proposed inflammatory nature of vasospasm and DCI, the use of statins has also been proposed and studied as a possible means to improve outcomes. Two recent meta-analyses, however, have failed to suggest that there is a significant enough benefit to warrant its routine use.^{75,76} We do not routinely use endothelin antagonists in patients with aSAH. Furthermore, we do not routinely start patients on statins when admitted with aSAH, but will continue them if the patient had been using the medication before the hemorrhage.

CARDIAC

Troponin elevation following subarachnoid hemorrhage is a well-known phenomenon. Elevation in troponin I was found to be associated with an increased risk of left ventricular dysfunction, pulmonary edema, DCI, and death or poor functional outcomes in a cohort of 253 patients at the time of discharge.⁷⁷ Cardiac dysfunction following aSAH (also known as stunned myocardium, and the more recently proposed neurogenic stress cardiomyopathy) presents a challenge to the management of these patients.⁷⁸ It manifests as an increase in troponins, multiterritorial regional wall-motion abnormalities on echocardiogram, electrocardiogram abnormalities, a chest radiograph with pulmonary edema, and a normal coronary angiogram.⁷⁸ These findings are important, as their presence may hinder the treatment of vasospasm and DCI. Tako-tsubo cardiomyopathy is a subset of cardiomyopathy that can be seen following aSAH, particularly in postmenopausal women.^{79,80} It is important to be aware of the diagnosis of cardiomyopathy following subarachnoid hemorrhage, as this has implications

in the augmentative therapy needed in DCI (ie, inotropic pressors may be more appropriate than vasoconstrictors). Cardiomyopathy, whether pre-existing or secondary to aSAH, can be detrimental in the setting of vasospasm when hemodynamic augmentation (triple-H therapy) is required. We previously reported on the successful use of an intra-aortic balloon counterpulsation pump in such a setting.⁸¹

Although the causality has not been well established, it has been shown that bradycardia, tachycardia, and nonspecific ST-wave and T-wave abnormalities have been associated with mortality following aSAH.⁸²

PULMONARY

Pulmonary complications have been reported in 22% of patients with aSAH, with pneumonia and congestive heart failure being the most common.⁸³ In their study of 305 patients, Friedman and colleagues⁸³ found that the incidence of symptomatic vasospasm was higher in patients with pulmonary complications. This finding is important, as it may relate to the fact that optimal treatment of vasospasm/DCI can be limited by the presence of pulmonary complications. Mechanisms by which pulmonary function is impaired following subarachnoid hemorrhage include pneumonia, pulmonary edema, atelectasis, acute lung injury, and acute respiratory distress syndrome.^{84–86}

RENAL

Fluid Balance

An understanding of the fluid balance of patients with aSAH is important,⁸⁷ as is sodium balance, which is closely linked to fluid physiology. Standard calculations of fluid-balance measurements do not accurately predict actual circulating blood volumes as measured by pulse dye densitometry.⁸⁸ Given these findings, in a prospective controlled study Hoff and colleagues⁸⁹ used pulse dye densitometry to measure blood volumes daily in 102 patients in the first 10 days following SAH. In the intervention group, fluid management was based on blood-volume measurements, compared with the control group in which fluid management was based on fluid balance. The investigators found that severe hypovolemia (defined as blood volume <50 mL/kg) was seen more often in patients being managed by fluid calculation alone.

Swan-Ganz catheterization is one means of invasive measurement of hemodynamic parameters. However, there are numerous complications associated with this method.⁹⁰ One more recent method of monitoring volume status is by means of

transpulmonary thermodilution monitoring with the PiCCO system.⁹¹ The effectiveness of the PiCCO system, compared with conventional pulmonary artery catheter-derived measurements, was compared in 16 patients with subarachnoid hemorrhage.⁹² Cardiac output by the PiCCO system showed high correlation and low error compared with conventional catheter-based measurements. Once the accuracy of the PiCCO system was validated in the 16 patients, 100 subsequent patients were then randomized to either PiCCO or traditional catheters and the outcomes compared. Patients receiving early goal-directed therapy by PiCCO had decreased occurrences of vasospasm and cardiopulmonary complications compared with those managed by standard management based on use of central venous or pulmonary artery catheters. In the NCCU, we prefer the use of the PiCCO system to Swan-Ganz catheterization when more precise hemodynamic monitoring is needed beyond a central venous line.

Fluid-balance goals should constantly be assessed in patients with aSAH. The role of prophylactic hypervolemia has been studied. Eighty-two patients were randomized to either hypervolemia or euvolemia in a prospective randomized trial following aneurysm clipping.⁵⁸ There was no benefit in CBF in the patients randomized to hypervolemia. Similarly, in their study of 32 patients randomized to triple-H therapy or euvolemia, Egge and colleagues⁹³ did not find any benefit to prophylactic triple-H therapy. Given these data and the complications associated with hypervolemia, we aim for a goal of euvolemia unless otherwise indicated (ie, vasospasm/DCI). To this end, 0.9% normal saline is routinely used as maintenance fluids. In the setting of CSW or syndrome of inappropriate antidiuretic hormone secretion (SIADH), however, hypertonic saline may be required.

Sodium Goals

Derangements in maintenance levels of blood sodium are common in aSAH. Sodium levels are important, as outcomes have been associated with abnormal values.⁹⁴ Two common causes of hyponatremia in patients with aSAH are CSW and SIADH. In CSW there is a renal loss of sodium, resulting in diuresis and hypovolemia, whereas in SIADH there is a retention of free water, leading to euvolemia or hypervolemia.⁹⁵ It is important to distinguish the 2 disorders clinically, as treatment will vary depending on the origin of the hyponatremia. We have previously reported favorable experience using 3% sodium chloride/acetate for hyponatremia in 29 patients with symptomatic

vasospasm.⁹⁶ Most patients with hyponatremia after aSAH have CSW and not SIADH.

Corticosteroids have been used to treat hyponatremia in aSAH. In one randomized, placebo-controlled trial, hydrocortisone (Cortef) was effectively used to prevent hyponatremia, although there was no overall difference in patient outcome.⁹⁷ Fludrocortisone (Florinef) has also been shown to be effective in preventing natriuresis in randomized studies.^{98,99} A recent study showed that early use of fludrocortisone was effective in preventing symptomatic vasospasm, but had no effect on overall outcomes.¹⁰⁰ We use fludrocortisone when the diagnosis of CSW has been made by presence of excessive diuresis accompanied by declining levels of blood sodium; we do not routinely use corticosteroids in a prophylactic manner.

INFECTIOUS DISEASE

Fever

Fever following subarachnoid hemorrhage is common. Predictors include poor Hunt-Hess grade and the presence of intraventricular hemorrhage.¹⁰¹ Of importance, refractory fever following SAH is associated with increased mortality and worse outcomes.^{101,102} Despite this, the role of fever reduction in improving outcomes is not well known. The side effects of treating fever either by pharmacologic means (ie, potential antiplatelet effects of nonsteroidal anti-inflammatories) or by cooling devices such as cooling blankets and intravascular devices (ie, shivering) must be weighed against the potential benefit in reducing the patient's temperature. In the NCCU, we treat fevers (>38.4°C) first with acetaminophen, and simultaneously send a diagnostic workup for the etiology of the fever and treatment of identifiable causes. If this is ineffective, methods of cooling such as surface cooling devices are used. Initial fever workup consists of urine analysis, urine culture, blood cultures, and chest radiography. CSF studies are sent on patients with ventriculostomies or lumbar catheters. If the patient has had an intracranial procedure but does not have a CSF drain in place, consideration is given to LP to obtain CSF in the appropriate clinical setting. Thorough investigation to identify and treat infectious causes of fever is prudent, as both pneumonia and bloodstream infections are independently associated with death or severe disability at 3 months.¹⁰³ Of importance is that delayed fever may also be present in the setting of vasospasm.¹⁰⁴

Periprocedural Antibiotics

Periprocedural antibiotics are given for invasive procedures involving the central nervous system.

We use cefazolin (Ancef, Kefzol) unless the patient has an allergy or contraindication, in which case clindamycin (Cleocin) is substituted. One dose is given immediately before placement of ventriculostomy or lumbar drain. For patients undergoing craniotomy, antibiotics are continued for an additional 24 hours after surgery while in the NCCU.

ENDOCRINE

Glucose Control

Persistently elevated glucose (>200 mg/dL for 2 or more consecutive days), has been shown to result in patients being 7 times more likely of having a poor outcome at 10 months after treatment for aSAH than those patients who did not have persistently elevated glucose.¹⁰⁵ Furthermore, elevated glucose levels at admission are also associated with an increased risk of poor outcome.¹⁰⁶ Prolonged elevated glucose (ie, over a week) is also associated with worse outcomes.¹⁰⁷ However, treatment of hyperglycemia can lead to increased incidence of hypoglycemia, which has been shown, in both the SAH literature and the general medical literature, to be associated with worse outcomes.^{108,109} As such, we place patients on an insulin sliding scale to target a glucose goal of 150 mg/dL or less at the time of admission. Continuous insulin infusions are only used when hyperglycemia is refractory to intermittent subcutaneous insulin dosing regimens.

HEMATOLOGY

Anemia

The ideal hemoglobin goal in patients with aSAH is not certain. Early animal data suggested that a hematocrit near 30% was optimal for protecting the brain in a canine model of ischemia.¹¹⁰ Subsequently, several human studies have shown that anemia and lower hemoglobin values are associated with worse outcomes in patients with aSAH, and that higher hemoglobin is associated with improved outcomes.^{111–114} A recent prospective, randomized trial randomized 44 patients to a hemoglobin goal of at least either 10 or 11.5 g/dL to evaluate the safety of this practice.¹¹⁵ Although those in the higher hemoglobin group received more transfusions, this was found to be safe with similar safety and outcome end points. This finding is an important one for the SAH population, as studies from the critical care literature have suggested that a higher hemoglobin goal is not necessarily better and may actually result in worse outcomes.¹¹⁶ We aim for a hemoglobin goal of at least 10 g/dL, and transfuse accordingly.

Deep Venous Thrombosis

The incidence of DVT in patients with SAH varies. Ray and colleagues¹¹⁷ report an incidence of 18% in 250 patients with aSAH over a 4-year period, and Mack and colleagues¹¹⁸ report an incidence of 3.4% in 178 patients who had screening lower extremity Doppler ultrasonography. A recent meta-analysis looking at venous thromboembolism (VTE) prevention, with pooled data from 30 studies with a total of 7779 patients, showed that low molecular weight heparin and intermittent compression devices were effective in decreasing the rate of VTE.¹¹⁹

Typically all patients at our center receive compression stockings and sequential compression devices at the time of admission. We will typically hold medical thromboprophylaxis until definitive treatment of the aneurysm. At this point, 5000 units unfractionated heparin given subcutaneously every 8 to 12 hours is begun, starting 24 hours after treatment. We do not routinely use low molecular weight heparin, although this may be considered for patients at high risk for DVT.¹²⁰ Rates of intracranial hemorrhage vary depending on the method of prophylaxis used. Lowest rates were seen if no heparin was used (0.04 per 1000 patients), and was 0.35 per 1000 patients if unfractionated heparin was used. Rates were highest in the group receiving low molecular weight heparin (1.52 per 1000 patients).¹¹⁹

NCCU MANAGEMENT OF ENDOVASCULAR VERSUS SURGICALLY TREATED PATIENTS

It should be noted that patients treated endovascularly rather than with surgical clipping of aneurysms following aSAH present unique challenges, which vary with treatment modality. Some aneurysms are best treated with endovascular therapy (ie, mid-basilar aneurysms), whereas others are best treated with microsurgical clipping (ie, MCA aneurysms). However, the decision of whether to treat a particular aneurysm with microsurgical clipping versus endovascular occlusion is complex and beyond the scope of this article. We have previously reviewed this literature, and in general favor surgical clipping over endovascular therapy in aSAH patients.¹²¹ Regardless of which treatment modality is ultimately used, it is important that those caring for these patients in the NCCU recognize the differences in their management. Patients who have had coil embolization or stent-assisted coil embolization, may require antiplatelet therapy, which creates a challenge if the patient requires subsequent invasive interventions (ventriculostomy, lumbar drain, craniotomy, and so

forth). For example, rates of hemorrhagic complications associated with ventriculostomy placement in aSAH patients undergoing stent-assisted coiling, and thus on dual antiplatelet therapy, are higher than those undergoing coiling without a stent.¹²² Patients who have undergone craniotomies are susceptible to postoperative complications (eg, wound infections, postoperative hematoma) that patients treated by endovascular means are not. It is important for the practitioner caring for these patients to be aware of these differences.

SUMMARY

aSAH can be a devastating disease. Those patients who survive the initial hemorrhage are best cared for in specialized NCCUs with personnel well trained in the management of this disease. Despite the progress made over the last decades, there still remains a paucity of high-quality evidence with which to guide the management of these patients. This article aims to provide those caring for these patients with a brief review of some of the literature combined with our own experiences. **Table 1** provides an outline for admission orders and a daily rounding template based on this experience, to help those who take on the challenge of managing this disease.

REFERENCES

1. Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* 2009;8(4):355–69.
2. Diring MN, Bleck TP, Claude Hemphill J, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. *Neurocrit Care* 2011;15:211–40.
3. Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2012;43:1711–37.
4. Cross DT, Tirschwell DL, Clark MA, et al. Mortality rates after subarachnoid hemorrhage: variations according to hospital case volume in 18 states. *J Neurosurg* 2003;99(5):810–7.
5. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. *Stroke* 2001;32(5):1176–80.
6. Bagley C. Blood in the cerebrospinal fluid resultant functional and organic alterations in the central nervous system A. Experimental data. *Arch Surg* 1928;17(1):18.
7. Dorai Z, Hynan LS, Kopitnik TA, et al. Factors related to hydrocephalus after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2003;52(4):763–71.
8. Komotar RJ, Olivi A, Rigamonti D, et al. Microsurgical fenestration of the lamina terminalis reduces the incidence of shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2002;51(6):1403–12 [discussion: 1412–3].
9. Komotar RJ, Hahn DK, Kim GH, et al. The impact of microsurgical fenestration of the lamina terminalis on shunt-dependent hydrocephalus and vasospasm after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2008;62(1):123–32 [discussion: 132–4].
10. van Gijn J, Hijdra A, Wijdicks EF, et al. Acute hydrocephalus after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1985;63(3):355–62.
11. de Oliveira JG, Beck J, Setzer M, et al. Risk of shunt-dependent hydrocephalus after occlusion of ruptured intracranial aneurysms by surgical clipping or endovascular coiling: a single-institution series and meta-analysis. *Neurosurgery* 2007;61(5):924–33 [discussion: 933–4].
12. Dehdashti AR, Rilliet B, Rufenacht DA, et al. Shunt-dependent hydrocephalus after rupture of intracranial aneurysms: a prospective study of the influence of treatment modality. *J Neurosurg* 2004;101(3):402–7.
13. Rincon F, Gordon E, Starke RM, et al. Predictors of long-term shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. Clinical article. *J Neurosurg* 2010;113(4):774–80.
14. O'Kelly CJ, Kulkarni AV, Austin PC, et al. Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: incidence, predictors, and revision rates. Clinical article. *J Neurosurg* 2009;111(5):1029–35.
15. Komotar RJ, Hahn DK, Kim GH, et al. Efficacy of lamina terminalis fenestration in reducing shunt-dependent hydrocephalus following aneurysmal subarachnoid hemorrhage: a systematic review. Clinical article. *J Neurosurg* 2009;111(1):147–54.
16. Little AS, Zabramski JM, Peterson M, et al. Ventriculoperitoneal shunting after aneurysmal subarachnoid hemorrhage: analysis of the indications, complications, and outcome with a focus on patients with borderline ventriculomegaly. *Neurosurgery* 2008;62(3):618–27 [discussion: 618–27].
17. Klopfenstein JD, Kim LJ, Feiz-Erfan I, et al. Comparison of rapid and gradual weaning from external ventricular drainage in patients with aneurysmal subarachnoid hemorrhage: a prospective randomized trial. *J Neurosurg* 2004;100(2):225–9.

18. Hellingman CA, van den Bergh WM, Beijer IS, et al. Risk of rebleeding after treatment of acute hydrocephalus in patients with aneurysmal subarachnoid hemorrhage. *Stroke* 2007;38(1):96–9.
19. McIver JI, Friedman JA, Wijidicks EF, et al. Preoperative ventriculostomy and rebleeding after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2002;97(5):1042–4.
20. Klimo P, Kestle JR, MacDonald JD, et al. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. *J Neurosurg* 2004;100(2):215–24.
21. Choi KS, Chun HJ, Yi HJ, et al. Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. *J Korean Neurosurg Soc* 2009;46(2):93–8.
22. Ohman J. Hypertension as a risk factor for epilepsy after aneurysmal subarachnoid hemorrhage and surgery. *Neurosurgery* 1990;27(4):578–81.
23. Claassen J, Peery S, Kreiter KT, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. *Neurology* 2003;60(2):208–14.
24. Hart Y, Sneade M, Birks J, et al. Epilepsy after subarachnoid hemorrhage: the frequency of seizures after clip occlusion or coil embolization of a ruptured cerebral aneurysm: results from the International Subarachnoid Aneurysm Trial. *J Neurosurg* 2011;115(6):1159–68.
25. Lanzino G, D'Urso PI, Suarez J, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2011;15(2):247–56.
26. Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. *Stroke* 2005;36(3):583–7.
27. Chumnavej S, Dunn IF, Kim DH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. *Neurosurgery* 2007;60(1):99–102 [discussion: 102–3].
28. Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. *J Neurosurg* 2007;107(2):253–60.
29. Starke RM, Connolly ES, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Rebleeding after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2011;15(2):241–6.
30. Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet* 2005;366(9488):809–17.
31. Kassell NF, Torner JC, Jane JA, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: surgical results. *J Neurosurg* 1990;73(1):37–47.
32. Kassell NF, Torner JC, Haley EC, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: overall management results. *J Neurosurg* 1990;73(1):18–36.
33. Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. *Arch Neurol* 2005;62(3):410–6.
34. Lord AS, Fernandez L, Schmidt JM, et al. Effect of rebleeding on the course and incidence of vasospasm after subarachnoid hemorrhage. *Neurology* 2011;78(1):31–7.
35. Johnston SC, Dowd CF, Higashida RT, et al. Predictors of rehemorrhage after treatment of ruptured intracranial aneurysms: the Cerebral Aneurysm Rupture After Treatment (CARAT) study. *Stroke* 2008;39(1):120–5.
36. Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev* 2003;(2):CD001245.
37. Hillman J, Fridriksson S, Nilsson O, et al. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. *J Neurosurg* 2002;97(4):771–8.
38. Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. *Stroke* 2008;39(9):2617–21.
39. Brown RJ, Kumar A, Dhar R, et al. The relationship between delayed infarcts and angiographic vasospasm after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2013. [Epub ahead of print].
40. Robertson EG. Cerebral lesions due to intracranial aneurysms. *Brain* 1949;72(Pt. 2):150–85.
41. Ecker A, Riemenschneider PA. Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. *J Neurosurg* 1951;8(6):660–7.
42. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. *Stroke* 2010;41(10):2391–5.
43. Frontera JA, Fernandez A, Schmidt JM, et al. Clinical response to hypertensive hypervolemic therapy and outcome after subarachnoid hemorrhage. *Neurosurgery* 2010;66(1):35–41 [discussion: 41].

44. Vergouwen MD, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. *Neurocrit Care* 2011; 15(2):308–11.
45. Frontera JA, Fernandez A, Schmidt JM, et al. Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? *Stroke* 2009;40(6):1963–8.
46. Carrera E, Schmidt JM, Oddo M, et al. Transcranial Doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage. *Neurosurgery* 2009;65(2):316–23 [discussion: 323–4].
47. Lysakowski C, Walder B, Costanza MC, et al. Transcranial Doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. *Stroke* 2001; 32(10):2292–8.
48. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage. *N Engl J Med* 1983;308(11):619–24.
49. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev* 2007;(3):CD000277.
50. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid hemorrhage. *Stroke* 2008;39:514–5.
51. Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. *Lancet* 2012;380(9836):44–9.
52. Wise G, Sutter R, Burkholder J. The treatment of brain ischemia with vasopressor drugs. *Stroke* 1972;3(2):135–40.
53. Hunt WE, Kosnik EJ. Timing and perioperative care in intracranial aneurysm surgery. *Clin Neurosurg* 1974;21:79–89.
54. Wood JH, Fleischer AS. Observations during hypervolemic hemodilution of patients with acute focal cerebral ischemia. *JAMA* 1982;248(22): 2999–3004.
55. Kassell NF, Peerless SJ, Durward QJ, et al. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. *Neurosurgery* 1982;11(3):337–43.
56. Dankbaar JW, Slooter AJ, Rinkel GJ, et al. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. *Crit Care* 2010;14(1):R23.
57. Raabe A, Beck J, Keller M, et al. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. *J Neurosurg* 2005;103(6):974–81.
58. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. *Stroke* 2000;31(2):383–91.
59. Sen J, Belli A, Albon H, et al. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. *Lancet Neurol* 2003;2(10):614–21.
60. Hoh BL, Carter BS, Ogilvy CS. Risk of hemorrhage from unsecured, unruptured aneurysms during and after hypertensive hypervolemic therapy. *Neurosurgery* 2002;50(6):1207–11 [discussion: 1211–2].
61. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. *Stroke* 2007;38(5):1655–711.
62. Zubkov YN, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal SAH. *Acta Neurochir* 1984;70(1–2):65–79.
63. Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. *Neurosurg Clin N Am* 2005;16(3): 501–16, vi.
64. Kimball MM, Velat GJ, Hoh BL, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Critical care guidelines on the endovascular management of cerebral vasospasm. *Neurocrit Care* 2011;15:336–41.
65. Froehler MT, Kooshkabadi A, Miller-Lotan R, et al. Vasospasm after subarachnoid hemorrhage in haptoglobin 2-2 mice can be prevented with a glutathione peroxidase mimetic. *J Clin Neurosci* 2010;17(9):1169–72.
66. Pradilla G, Chaichana KL, Hoang S, et al. Inflammation and cerebral vasospasm after subarachnoid hemorrhage. *Neurosurg Clin N Am* 2010; 21(2):365–79.
67. Chaichana KL, Pradilla G, Huang J, et al. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. *World Neurosurg* 2010;73(1):22–41.
68. Gallia GL, Tamargo RJ. Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. *Neurol Res* 2006;28(7):750–8.

69. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. *Stroke* 2000;31(12):2971–5.
70. Ardelit A. From bench-to-bedside in catastrophic cerebrovascular disease: development of drugs targeting the endothelin axis in subarachnoid hemorrhage-related vasospasm. *Neurol Res* 2012;34:195–210.
71. MacDonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. *Stroke* 2008;39(11):3015–21.
72. MacDonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). *Lancet Neurol* 2011;10(7):618–25.
73. MacDonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. *Stroke* 2012;43(6):1463–9.
74. Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. *Stroke* 2012;43(10):2671–6.
75. Kramer AH, Fletcher JJ. Statins in the management of patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *Neurocrit Care* 2010;12(2):285–96.
76. Vergouwen MD, de Haan RJ, Vermeulen M, et al. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. *Stroke* 2010;41(1):e47–52.
77. Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. *Circulation* 2005;112(18):2851–6.
78. Lee VH, Oh JK, Mulvagh SL, et al. Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2006;5(3):243–9.
79. Lee VH, Connolly HM, Fulgham JR, et al. Tako-tsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage: an underappreciated ventricular dysfunction. *J Neurosurg* 2006;105(2):264–70.
80. Ako J, Honda Y, Fitzgerald PJ. Tako-tsubo-like left ventricular dysfunction. *Circulation* 2003;108(23):e158 [author reply: e158].
81. Lazaridis C, Pradilla G, Nyquist PA, et al. Intra-aortic balloon pump counterpulsation in the setting of subarachnoid hemorrhage, cerebral vasospasm, and neurogenic stress cardiomyopathy. Case report and review of the literature. *Neurocrit Care* 2010;13(1):101–8.
82. Coghlan LA, Hindman BJ, Bayman EO, et al. Independent associations between electrocardiographic abnormalities and outcomes in patients with aneurysmal subarachnoid hemorrhage: findings from the intraoperative hypothermia aneurysm surgery trial. *Stroke* 2009;40(2):412–8.
83. Friedman JA, Pichelmann MA, Piepgras DG, et al. Pulmonary complications of aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2003;52(5):1025–31 [discussion: 1031–2].
84. Vespa PM, Bleck TP. Neurogenic pulmonary edema and other mechanisms of impaired oxygenation after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2004;1(2):157–70.
85. Kahn JM, Caldwell EC, Deem S, et al. Acute lung injury in patients with subarachnoid hemorrhage: incidence, risk factors, and outcome. *Crit Care Med* 2006;34(1):196–202.
86. Bruder N, Rabinstein A. Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Cardiovascular and pulmonary complications of aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2011;15(2):257–69.
87. Gress DR. Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Monitoring of volume status after subarachnoid hemorrhage. *Neurocrit Care* 2011;15(2):270–4.
88. Hoff RG, van Dijk GW, Algra A, et al. Fluid balance and blood volume measurement after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2008;8(3):391–7.
89. Hoff R, Rinkel G, Verweij B, et al. Blood volume measurement to guide fluid therapy after aneurysmal subarachnoid hemorrhage: a prospective controlled study. *Stroke* 2009;40(7):2575–7.
90. Rosenwasser RH, Jallo JI, Getch CC, et al. Complications of Swan-Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. *Neurosurgery* 1995;37(5):872–5 [discussion: 875–6].
91. Mutoh T, Kazumata K, Ajiki M, et al. Goal-directed fluid management by bedside transpulmonary hemodynamic monitoring after subarachnoid hemorrhage. *Stroke* 2007;38(12):3218–24.
92. Mutoh T, Kazumata K, Ishikawa T, et al. Performance of bedside transpulmonary thermodilution monitoring for goal-directed hemodynamic management after subarachnoid hemorrhage. *Stroke* 2009;40(7):2368–74.
93. Egge A, Waterloo K, Sjøholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical,

- prospective, randomized, controlled study. *Neurosurgery* 2001;49(3):593–605 [discussion: 605–6].
94. Qureshi AI, Suri MF, Sung GY, et al. Prognostic significance of hyponatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2002;50(4):749–55 [discussion: 755–6].
 95. Harrigan MR. Cerebral salt wasting syndrome. *Crit Care Clin* 2001;17(1):125–38.
 96. Suarez JI, Qureshi AI, Parekh PD, et al. Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. *J Neurosurg Anesthesiol* 1999;11(3):178–84.
 97. Katayama Y, Haraoka J, Hirabayashi H, et al. A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. *Stroke* 2007;38(8):2373–5.
 98. Hasan D, Lindsay KW, Wijedicks EF, et al. Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. *Stroke* 1989;20(9):1156–61.
 99. Mori T, Katayama Y, Kawamata T, et al. Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1999;91(6):947–52.
 100. Nakagawa I, Hironaka Y, Nishimura F, et al. Early inhibition of natriuresis suppresses symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. *Cerebrovasc Dis* 2013;35(2):131–7.
 101. Fernandez A, Schmidt JM, Claassen J, et al. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. *Neurology* 2007;68(13):1013–9.
 102. Naidech AM, Bendok BR, Bernstein RA, et al. Fever burden and functional recovery after subarachnoid hemorrhage. *Neurosurgery* 2008;63(2):212–7 [discussion: 217–8].
 103. Frontera JA, Fernandez A, Schmidt JM, et al. Impact of nosocomial infectious complications after subarachnoid hemorrhage. *Neurosurgery* 2008;62(1):80–7 [discussion: 87].
 104. Rousseaux P, Scherpereel B, Bernard MH, et al. Fever and cerebral vasospasm in ruptured intracranial aneurysms. *Surg Neurol* 1980;14(6):459–65.
 105. McGirt MJ, Woodworth GF, Ali M, et al. Persistent perioperative hyperglycemia as an independent predictor of poor outcome after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2007;107(6):1080–5.
 106. Krzyt ND, Biessels GJ, de Haan RJ, et al. Hyperglycemia and clinical outcome in aneurysmal subarachnoid hemorrhage: a meta-analysis. *Stroke* 2009;40(6):e424–30.
 107. Frontera JA, Fernandez A, Claassen J, et al. Hyperglycemia after SAH: predictors, associated complications, and impact on outcome. *Stroke* 2006;37(1):199–203.
 108. Naidech AM, Levasseur K, Liebling S, et al. Moderate hypoglycemia is associated with vasospasm, cerebral infarction, and 3-month disability after subarachnoid hemorrhage. *Neurocrit Care* 2010;12(2):181–7.
 109. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360(13):1283–97.
 110. Lee SH, Heros RC, Mullan JC, et al. Optimum degree of hemodilution for brain protection in a canine model of focal cerebral ischemia. *J Neurosurg* 1994;80(3):469–75.
 111. Kramer AH, Zygun DA, Bleck TP, et al. Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2009;10(2):157–65.
 112. Kramer AH, Gurka MJ, Nathan B, et al. Complications associated with anemia and blood transfusion in patients with aneurysmal subarachnoid hemorrhage. *Crit Care Med* 2008;36(7):2070–5.
 113. Naidech AM, Drescher J, Ault ML, et al. Higher hemoglobin is associated with less cerebral infarction, poor outcome, and death after subarachnoid hemorrhage. *Neurosurgery* 2006;59(4):775–9 [discussion: 779–80].
 114. Naidech AM, Jovanovic B, Wartenberg KE, et al. Higher hemoglobin is associated with improved outcome after subarachnoid hemorrhage. *Crit Care Med* 2007;35(10):2383–9.
 115. Naidech AM, Shaibani A, Garg RK, et al. Prospective, randomized trial of higher goal hemoglobin after subarachnoid hemorrhage. *Neurocrit Care* 2010;13(3):313–20.
 116. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999;340(6):409–17.
 117. Ray WZ, Strom RG, Blackburn SL, et al. Incidence of deep venous thrombosis after subarachnoid hemorrhage. *J Neurosurg* 2009;110(5):1010–4.
 118. Mack WJ, Ducruet AF, Hickman ZL, et al. Doppler ultrasonography screening of poor-grade subarachnoid hemorrhage patients increases the diagnosis of deep venous thrombosis. *Neurol Res* 2008;30(9):889–92.
 119. Collen JF, Jackson JL, Shorr AF, et al. Prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Chest* 2008;134(2):237–49.
 120. Vespa P, Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Deep venous thrombosis prophylaxis. *Neurocrit Care* 2011;15(2):295–7.

121. Raja PV, Huang J, Germanwala AV, et al. Microsurgical clipping and endovascular coiling of intracranial aneurysms: a critical review of the literature. *Neurosurgery* 2008;62(6):1187–202 [discussion: 1202–3].
122. Kung DK, Policeni BA, Capuano AW, et al. Risk of ventriculostomy-related hemorrhage in patients with acutely ruptured aneurysms treated using stent-assisted coiling. *J Neurosurg* 2011;114(4):1021–7.